In lupus, something goes wrong with the immune system, which is the part of the body that fights off viruses, bacteria, and germs (“foreign invaders,” like the flu).
Normally our immune systems produce antibodies that protect the body from these invaders. Antibodies are proteins in the blood that the body produces to fight off foreign agents. Antibodies do this by creating an immunity against unfamiliar microorganisms.
Autoimmune means your immune system cannot tell the difference between these foreign invaders and your body’s healthy tissues and creates autoantibodies that attack and destroy healthy tissue (“auto” means “self”).
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.
